S Shadid1, M D Jensen. 1. Endocrine Research Unit, Mayo Clinic, 5-194 Joseph, 200 1st Street SW, Rochester, MN 55905, USA.
Abstract
AIMS/HYPOTHESIS: Plasma NEFA concentrations are largely determined by adipose tissue lipolysis. Insulin suppression of lipolysis is commonly impaired with insulin resistance and improves with thiazolidinedione treatment of type 2 diabetes. The present studies were designed to assess the effects of thiazolidinedione on NEFA (oleate) metabolism that are independent of improved glycaemic control. MATERIALS AND METHODS: We measured plasma oleate concentration and flux ([(3)H]oleate), glucose kinetics ([6-(2)H(2)]glucose) and substrate oxidation (indirect calorimetry) before and after pioglitazone (30 mg/day for approximately 20 weeks) in 20 non-diabetic adults with upper body obesity. To assess the effects of improved insulin sensitivity per se we performed the same measurements in a matched group of volunteers treated with diet/exercise. Half of the two groups underwent these measurements during a hyperinsulinaemic-euglycaemic clamp, and the other half had their measurements taken during a (control) saline infusion before and after the intervention. RESULTS: Both interventions increased insulin-stimulated glucose disposal and reduced plasma oleate concentrations during the insulin clamp. After diet/exercise, oleate flux decreased (p=0.03) during the insulin clamp and oleate clearance remained unchanged (p=0.55), whereas in the pioglitazone group, oleate flux during the clamp was unchanged (p=0.97) and oleate clearance increased (p=0.003). Oleate clearance in the saline control condition was increased in the pioglitazone group compared with the diet/exercise group (p=0.02). CONCLUSIONS/ INTERPRETATION: In insulin-resistant, non-diabetic adults, pioglitazone increases NEFA clearance during physiological hyperinsulinaemia, whereas improved insulin sensitivity achieved by diet/exercise does not alter NEFA clearance but enhances insulin suppression of NEFA release. This action of pioglitazone may contribute to improved glucose metabolism in type 2 diabetes.
RCT Entities:
AIMS/HYPOTHESIS: Plasma NEFA concentrations are largely determined by adipose tissue lipolysis. Insulin suppression of lipolysis is commonly impaired with insulin resistance and improves with thiazolidinedione treatment of type 2 diabetes. The present studies were designed to assess the effects of thiazolidinedione on NEFA (oleate) metabolism that are independent of improved glycaemic control. MATERIALS AND METHODS: We measured plasma oleate concentration and flux ([(3)H]oleate), glucose kinetics ([6-(2)H(2)]glucose) and substrate oxidation (indirect calorimetry) before and after pioglitazone (30 mg/day for approximately 20 weeks) in 20 non-diabetic adults with upper body obesity. To assess the effects of improved insulin sensitivity per se we performed the same measurements in a matched group of volunteers treated with diet/exercise. Half of the two groups underwent these measurements during a hyperinsulinaemic-euglycaemic clamp, and the other half had their measurements taken during a (control) saline infusion before and after the intervention. RESULTS: Both interventions increased insulin-stimulated glucose disposal and reduced plasma oleate concentrations during the insulin clamp. After diet/exercise, oleate flux decreased (p=0.03) during the insulin clamp and oleate clearance remained unchanged (p=0.55), whereas in the pioglitazone group, oleate flux during the clamp was unchanged (p=0.97) and oleate clearance increased (p=0.003). Oleate clearance in the saline control condition was increased in the pioglitazone group compared with the diet/exercise group (p=0.02). CONCLUSIONS/ INTERPRETATION: In insulin-resistant, non-diabetic adults, pioglitazone increases NEFA clearance during physiological hyperinsulinaemia, whereas improved insulin sensitivity achieved by diet/exercise does not alter NEFA clearance but enhances insulin suppression of NEFA release. This action of pioglitazone may contribute to improved glucose metabolism in type 2 diabetes.
Authors: H O Steinberg; M Tarshoby; R Monestel; G Hook; J Cronin; A Johnson; B Bayazeed; A D Baron Journal: J Clin Invest Date: 1997-09-01 Impact factor: 14.808
Authors: Adam B Mayerson; Ripudaman S Hundal; Sylvie Dufour; Vincent Lebon; Douglas Befroy; Gary W Cline; Staffan Enocksson; Silvio E Inzucchi; Gerald I Shulman; Kitt F Petersen Journal: Diabetes Date: 2002-03 Impact factor: 9.461
Authors: John M Miles; David Wooldridge; Wayne J Grellner; Sheryl Windsor; William L Isley; Samuel Klein; William S Harris Journal: Diabetes Date: 2003-03 Impact factor: 9.461
Authors: Kazanna C Hames; Maria Morgan-Bathke; Debra A Harteneck; Lendia Zhou; John D Port; Ian R Lanza; Michael D Jensen Journal: Am J Clin Nutr Date: 2017-04-19 Impact factor: 7.045
Authors: Tamara Tchkonia; Thomas Thomou; Yi Zhu; Iordanes Karagiannides; Charalabos Pothoulakis; Michael D Jensen; James L Kirkland Journal: Cell Metab Date: 2013-04-11 Impact factor: 27.287
Authors: Brian D Fink; Yunxia O'Malley; Brian L Dake; Nicolette C Ross; Thomas E Prisinzano; William I Sivitz Journal: PLoS One Date: 2009-01-22 Impact factor: 3.240
Authors: Marleen Kars; Ling Yang; Margaret F Gregor; B Selma Mohammed; Terri A Pietka; Brian N Finck; Bruce W Patterson; Jay D Horton; Bettina Mittendorfer; Gökhan S Hotamisligil; Samuel Klein Journal: Diabetes Date: 2010-06-03 Impact factor: 9.461
Authors: Peter Ahiawodzi; Luc Djousse; Joachim H Ix; Jorge R Kizer; Russell P Tracy; Alice Arnold; Anne Newman; Kenneth J Mukamal Journal: J Am Geriatr Soc Date: 2020-09-22 Impact factor: 5.562
Authors: Justin C Brown; Michael R Rickels; Andrea B Troxel; Babette S Zemel; Nevena Damjanov; Bonnie Ky; Andrew D Rhim; Anil K Rustgi; Kerry S Courneya; Kathryn H Schmitz Journal: Endocr Relat Cancer Date: 2017-10-10 Impact factor: 5.678